Clinical Trials on Multiple Myeloma(MM) in India

Total 93 results

Piramal Enterprises Limited

Completed

Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

India
Amgen

Active, not recruiting

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma

India
All India Institute of Medical Sciences, New Delhi

Unknown

Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation (Ara-c)

Acute Myeloid Leukemia

India
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, Italy, Germany, France, Japan, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, Poland, Australia, Netherlands, United Kingdom, India, China
Gleneagles Hospital
Samsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaborators

Completed

Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma (dtZ)

Multiple Myeloma

Korea, Republic of, Singapore, India
Eisai Inc.

Withdrawn

A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Acute Myelogenous Leukemia (AML)

India
Command Hospital, India

Unknown

To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission

Chronic Myeloid Leukemia | Treatment Free Remission

India
Christian Medical College, Vellore, India

Unknown

Proteasome Inhibition in Acute Promyelocytic Leukemia (PIAPL)

Relapsed Acute Promyelocytic Leukemia

India
Johnson & Johnson Private Limited

Completed

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

Multiple Myeloma

India
Dr Atul Sharma

Unknown

Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy

Acute Myeloid Leukemia | Chemotherapy Induced Vomiting

India
Janssen Research & Development, LLC

Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

Relapsed or Refractory Multiple Myeloma

United States, Canada, Australia, China, Germany, Belgium, Malaysia, Turkey, Japan, Israel, Sweden, Spain, United Kingdom, Czechia, Denmark, Brazil, Italy, France, Netherlands, Poland, Austria, Portugal, Greece, India
Pharmacosmos A/S

Completed

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

Non-myeloid Malignancies | Chemotherapy Induced Anaemia

India
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)

Relapsed or Refractory Multiple Myeloma

United States, Austria, Denmark, Canada, Australia, China, Spain, Germany, United Kingdom, Hungary, Taiwan, Israel, Japan, India, Norway, Brazil, Italy, Greece, Korea, Republic of, Colombia, Singapore, Netherlands, Argentina, Hong Kong, Romani... and more
Celgene

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

Relapsed or Refractory Multiple Myeloma

United States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, Czechia, Chile, New... and more
Novo Cellular Medicine Institute LLP

Unknown

A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Multiple Sclerosis, Relapsing-Remitting

India, Trinidad and Tobago
Chaitanya Hospital, Pune

Unknown

Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)

Multiple Sclerosis

India
The Centre for Advanced Research & Development,...

Unknown

Cytotron® Delivered Rotational Field Quantum Nuclear Magnetic Resonance Therapy for Multiple Sclerosis (RFQMR)

Multiple Sclerosis

India
Aurigene Discovery Technologies Limited

Recruiting

A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (BHARAT-1)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Non Hodgkin Lymphoma | Solid Tumor, Adult

India
Human Genome Sciences Inc.

Completed

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada, Australia, India
Christian Medical College, Vellore, India
Ministry of Science and Technology, India

Unknown

Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (IAPLSG04)

Acute Promyelocytic Leukemia

India
Sanofi

Completed

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (SAFE)

Relapsing Multiple Sclerosis

India
Marco J. Bruno
Boston Scientific Corporation

Recruiting

Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries (PREVENT)

Cholangiopancreatography, Endoscopic Retrograde | Drug Resistance, Multiple, Bacterial

United States, India, Netherlands, Italy
Asian Institute of Gastroenterology, India

Recruiting

To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope (RDIH-01)

Hemostatic Disorder | POEMS Syndrome

India
Janssen Research & Development, LLC

Completed

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Multiple Myeloma

United States, Australia, France, Spain, Israel, India, Romania, Korea, Republic of, Singapore, Russian Federation, Poland
Amneal Pharmaceuticals, LLC
Accutest Research Laboratories (I) Pvt. Ltd.

Completed

Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions

Chronic Myeloid Leukemia | Gastrointestinal Stromal Tumor

India
Centocor, Inc.

Withdrawn

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Belgium, Poland, Bulgaria, Turkey, Ukraine, Australia, Korea, Republic of, New Zealand, Czech Republic, United Kingdom, Netherlands, India
Postgraduate Institute of Medical Education and...

Unknown

Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission

Chronic Myelogenous Leukemia | Short Stature

India
Celgene

Completed

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma (OPTIMUM)

Multiple Myeloma

India, Philippines, France, Portugal, Poland, South Africa, Bulgaria, Croatia, Czechia, Germany, Hungary, Italy, Serbia, Slovakia, United Kingdom
AstraZeneca

Recruiting

Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule. (CREATE)

Lung Malignancy

Turkey, India, Indonesia
GlaxoSmithKline

Recruiting

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM 14)

Multiple Myeloma

United States, Italy, Poland, Spain, Taiwan, Brazil, Greece, Ireland, Mexico, Canada, Korea, Republic of, Germany, France, Australia, United Kingdom, Argentina, India, Thailand, Switzerland
Karyopharm Therapeutics Inc

Active, not recruiting

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

Multiple Myeloma

United States, United Kingdom, Australia, Israel, Canada, Belgium, Austria, Czechia, Serbia, India, France, Italy, Russian Federation, Bulgaria, Germany, Greece, Hungary, Poland, Romania, Spain, Ukraine
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Celgene

Recruiting

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

Multiple Myeloma

Austria, China, Australia, Spain, Canada, United States, Korea, Republic of, Taiwan, Germany, Ireland, Argentina, Brazil, Mexico, Netherlands, Belgium, Czechia, France, Greece, Italy, Japan, Poland, Israel, United Kingdom, Norway, Denmark, Finla... and more
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
Celgene

Not yet recruiting

A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ALUMMINATE)

Multiple Myeloma

China, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Pfizer

Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

Multiple Myeloma

United States, Japan, Belgium, Netherlands, Australia, Austria, Taiwan, China, Spain, Canada, Korea, Republic of, Israel, Italy, Germany, Czechia, Norway, Finland, France, Sweden, Brazil, Greece, Turkey, Hungary, Poland, India
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (SELECTION)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Teva Branded Pharmaceutical Products R&D, Inc.
Cephalon; ChemGenex Pharmaceuticals

Completed

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Chronic Myeloid Leukemia

United States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
CENTOGENE GmbH Rostock

Withdrawn

Biomarker for Hyaline Fibromatosis Syndrome (BioHFS) (BioHFS)

Skin and Connective Tissue Diseases | Hyaline Membrane Disease | Hyalinosis | Juvenile Hyaline Fibromatosis | Fibromatosis Hyalinica Multiplex Juvenilis

Germany, Sri Lanka, India
Hoffmann-La Roche
PPD

Recruiting

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

Relapsing-Remitting Multiple Sclerosis

United States, Belgium, Canada, Spain, India, Italy, Mexico, Portugal, Austria, Brazil, United Kingdom, Germany, Netherlands, Serbia, Argentina, Australia, Bulgaria, France, Greece, Hungary, Poland, Ukraine, Estonia, Denmark, Croatia, Latvia and more
Teva Branded Pharmaceutical Products R&D, Inc.
Cephalon; ChemGenex Pharmaceuticals

Completed

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Chronic Myeloid Leukemia

United States, Canada, France, Germany, Hungary, India, Italy, Poland, Singapore, United Kingdom
Biogen
Alkermes, Inc.

Completed

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Relapsing Remitting Multiple Sclerosis

United States, Germany, Poland
Boehringer Ingelheim

Completed

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Leukemia, Myeloid, Acute

Korea, Republic of, Spain, Canada, Germany, Norway, Taiwan, Belgium, United States, Japan, Mexico, France, Greece, Italy, India, Austria, Portugal, Czechia, Russian Federation, Hungary, Brazil, Argentina, Finland, Netherlands, Poland, South...
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients (EXCHANGE)

Multiple Sclerosis | Relapsing Multiple Sclerosis | Advancing Multiple Sclerosis

United States, Puerto Rico
Biogen

Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

Relapsing-Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, France, Mexico, Poland, Spain, Germany, Belarus, Estonia, Latvia, Romania, Ukraine, Israel, New Zealand, Slovakia, Greece, India, Serbia, Ireland, Costa Rica, Canada, Belgium, Macedonia,... and more
Biogen

Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Czech Republic, France, Italy, Mexico, South Africa, United Kingdom, Germany, Poland, Romania, Ukraine, Netherlands, Austria, Canada, Israel, New Zealand, Slovakia, Greece, Serbia, India, Belgium, Switzerland, ... and more
Biogen
AbbVie

Terminated

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
Biogen

Completed

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

Relapsing-Remitting Multiple Sclerosis

United States, France, Germany, Spain, Belgium, Czechia, Switzerland, United Kingdom, Austria, New Zealand, Australia, South Africa, Ukraine, Italy, Slovakia, Greece, Poland, Israel, Netherlands, Bulgaria, Serbia, India, Romania, Estonia and more
Sellas Life Sciences Group

Active, not recruiting

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL)

Acute Myeloid Leukemia

United States, Spain, France, Taiwan, India, Hungary, Poland, Germany, Serbia, Greece

Clinical Trials on Multiple Myeloma(MM) in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations